BET inhibitors as novel therapeutic agents in breast cancer

Tumoral cells not only depend on oncogenic abnormalities to maintain its malignant phenotype but on non-oncogenic vulnerabilities. Targeting epigenomics can modify specific cellular functions required for malignant transformation. The Bromodomain (BRD) family mediates their effect by recruiting prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Ocaña, Alberto, Nieto-Jiménez, Cristina, Pandiella, Atanasio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642636/
https://www.ncbi.nlm.nih.gov/pubmed/29050361
http://dx.doi.org/10.18632/oncotarget.19744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642636/
https://www.ncbi.nlm.nih.gov/pubmed/29050361
http://dx.doi.org/10.18632/oncotarget.19744

Ejemplares similares